Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport. 2006

Yoshiyuki Shirasaka, and Masae Kawasaki, and Toshiyasu Sakane, and Hideaki Omatsu, and Yuka Moriya, and Tsutomu Nakamura, and Toshiyuki Sakaeda, and Katsuhiko Okumura, and Peter Langguth, and Shinji Yamashita
Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka, Japan. 04d101sy@edu.setsunan.ac.jp

The aim of this work is to develop a highly sensitive assay system for P-gp-mediated transport by using two methods, induction of P-gp and short-term culture of Caco-2 cells. To induce P-gp in Caco-2 cells, cells were cultured in vinblastine-containing medium. The mRNA level of P-gp was approximately 7-fold higher in Caco-2 cells cultured with vinblastine (P-gp-induced Caco-2 cells) than in control cells. Western blot analysis showed a significant increase in P-gp expression. After cell differentiation, the mRNA level of P-gp was downregulated, however, P-gp-induced Caco-2 cells still possessed a 5.6-fold higher mRNA level of P-gp compared to control cells. Polarized transport of substrate drugs was greater in the monolayer of P-gp-induced cells than in that of control cells. Moreover, we found that P-gp expression in Caco-2 cells could be further enhanced by applying the higher concentration of vinblastine. Transport activity of P-gp in Caco-2 cells cultured with higher concentration of vinblastine was markedly higher than that in P-gp-induced Caco-2 cells and was comparable with that in MDR1-MDCKII cells. In conclusion, this study provided a stable and highly sensitive in vitro assay system that can identify compounds that are subject to P-gp-mediated efflux.

UI MeSH Term Description Entries
D008840 Microfilament Proteins Monomeric subunits of primarily globular ACTIN and found in the cytoplasmic matrix of almost all cells. They are often associated with microtubules and may play a role in cytoskeletal function and/or mediate movement of the cell or the organelles within the cell. Actin Binding Protein,Actin-Binding Protein,Actin-Binding Proteins,Microfilament Protein,Actin Binding Proteins,Binding Protein, Actin,Protein, Actin Binding,Protein, Actin-Binding,Protein, Microfilament,Proteins, Actin-Binding,Proteins, Microfilament
D011802 Quinidine An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. Adaquin,Apo-Quinidine,Chinidin,Quincardine,Quinidex,Quinidine Sulfate,Quinora,Apo Quinidine,Sulfate, Quinidine
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003577 Cytochrome P-450 Enzyme System A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism. Cytochrome P-450,Cytochrome P-450 Enzyme,Cytochrome P-450-Dependent Monooxygenase,P-450 Enzyme,P450 Enzyme,CYP450 Family,CYP450 Superfamily,Cytochrome P-450 Enzymes,Cytochrome P-450 Families,Cytochrome P-450 Monooxygenase,Cytochrome P-450 Oxygenase,Cytochrome P-450 Superfamily,Cytochrome P450,Cytochrome P450 Superfamily,Cytochrome p450 Families,P-450 Enzymes,P450 Enzymes,Cytochrome P 450,Cytochrome P 450 Dependent Monooxygenase,Cytochrome P 450 Enzyme,Cytochrome P 450 Enzyme System,Cytochrome P 450 Enzymes,Cytochrome P 450 Families,Cytochrome P 450 Monooxygenase,Cytochrome P 450 Oxygenase,Cytochrome P 450 Superfamily,Enzyme, Cytochrome P-450,Enzyme, P-450,Enzyme, P450,Enzymes, Cytochrome P-450,Enzymes, P-450,Enzymes, P450,Monooxygenase, Cytochrome P-450,Monooxygenase, Cytochrome P-450-Dependent,P 450 Enzyme,P 450 Enzymes,P-450 Enzyme, Cytochrome,P-450 Enzymes, Cytochrome,Superfamily, CYP450,Superfamily, Cytochrome P-450,Superfamily, Cytochrome P450
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074011 Peptide Transporter 1 A proton-coupled symporter that transports OLIGOPEPTIDES and DIPEPTIDES. It localizes to the brush-border membrane of the INTESTINAL EPITHELIUM and plays a critical role in the assimilation of dietary proteins. Hydrogen-Peptide Cotransporter PepT1,Intestinal H+-Peptide Cotransporter,PepT1 Protein,Pept-1 Transporter,SLC15A1 Protein,Solute Carrier Family 15 Member 1,hPEPT1 (Cotransporter),H+-Peptide Cotransporter, Intestinal,Hydrogen Peptide Cotransporter PepT1,Intestinal H+ Peptide Cotransporter,PepT1, Hydrogen-Peptide Cotransporter,Pept 1 Transporter,Transporter, Pept-1
D000089762 Multidrug Resistance-Associated Protein 2 An ATP-BINDING CASSETTE TRANSPORTERS subfamily protein that is localized on the canalicular membrane of HEPATOCYTES, as well as on the apical membrane of EPITHELIAL CELLS of the DUODENUM, JEJUNUM and PROXIMAL RENAL TUBULE. ABCC2 Protein,CMOAT,CMOAT Protein,CMOAT Transport Protein,Canalicular Multispecific Organic Anion Transporter,MRP2 Protein, Multidrug Resistance,MRP2 Transport Protein,Multidrug Resistance Protein MRP2,Multidrug-Resistance Associated Protein 2,Multidrug Resistance Associated Protein 2,Transport Protein, CMOAT,Transport Protein, MRP2

Related Publications

Yoshiyuki Shirasaka, and Masae Kawasaki, and Toshiyasu Sakane, and Hideaki Omatsu, and Yuka Moriya, and Tsutomu Nakamura, and Toshiyuki Sakaeda, and Katsuhiko Okumura, and Peter Langguth, and Shinji Yamashita
January 2010, Biological & pharmaceutical bulletin,
Yoshiyuki Shirasaka, and Masae Kawasaki, and Toshiyasu Sakane, and Hideaki Omatsu, and Yuka Moriya, and Tsutomu Nakamura, and Toshiyuki Sakaeda, and Katsuhiko Okumura, and Peter Langguth, and Shinji Yamashita
January 2009, Phytotherapy research : PTR,
Yoshiyuki Shirasaka, and Masae Kawasaki, and Toshiyasu Sakane, and Hideaki Omatsu, and Yuka Moriya, and Tsutomu Nakamura, and Toshiyuki Sakaeda, and Katsuhiko Okumura, and Peter Langguth, and Shinji Yamashita
March 2002, Biological & pharmaceutical bulletin,
Yoshiyuki Shirasaka, and Masae Kawasaki, and Toshiyasu Sakane, and Hideaki Omatsu, and Yuka Moriya, and Tsutomu Nakamura, and Toshiyuki Sakaeda, and Katsuhiko Okumura, and Peter Langguth, and Shinji Yamashita
May 1993, Pharmaceutical research,
Yoshiyuki Shirasaka, and Masae Kawasaki, and Toshiyasu Sakane, and Hideaki Omatsu, and Yuka Moriya, and Tsutomu Nakamura, and Toshiyuki Sakaeda, and Katsuhiko Okumura, and Peter Langguth, and Shinji Yamashita
July 2012, The American journal of tropical medicine and hygiene,
Yoshiyuki Shirasaka, and Masae Kawasaki, and Toshiyasu Sakane, and Hideaki Omatsu, and Yuka Moriya, and Tsutomu Nakamura, and Toshiyuki Sakaeda, and Katsuhiko Okumura, and Peter Langguth, and Shinji Yamashita
August 2011, The Journal of pharmacy and pharmacology,
Yoshiyuki Shirasaka, and Masae Kawasaki, and Toshiyasu Sakane, and Hideaki Omatsu, and Yuka Moriya, and Tsutomu Nakamura, and Toshiyuki Sakaeda, and Katsuhiko Okumura, and Peter Langguth, and Shinji Yamashita
December 2002, Journal of pharmaceutical sciences,
Yoshiyuki Shirasaka, and Masae Kawasaki, and Toshiyasu Sakane, and Hideaki Omatsu, and Yuka Moriya, and Tsutomu Nakamura, and Toshiyuki Sakaeda, and Katsuhiko Okumura, and Peter Langguth, and Shinji Yamashita
February 2007, Journal of veterinary pharmacology and therapeutics,
Yoshiyuki Shirasaka, and Masae Kawasaki, and Toshiyasu Sakane, and Hideaki Omatsu, and Yuka Moriya, and Tsutomu Nakamura, and Toshiyuki Sakaeda, and Katsuhiko Okumura, and Peter Langguth, and Shinji Yamashita
December 2016, Fundamental & clinical pharmacology,
Yoshiyuki Shirasaka, and Masae Kawasaki, and Toshiyasu Sakane, and Hideaki Omatsu, and Yuka Moriya, and Tsutomu Nakamura, and Toshiyuki Sakaeda, and Katsuhiko Okumura, and Peter Langguth, and Shinji Yamashita
January 2007, Human psychopharmacology,
Copied contents to your clipboard!